Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy
Giulia Notini, Barbara Galbardi, Giulia Viale, Matteo M. Naldini et autres
1 citationnpj Precision Oncology
Luca Gianni
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
587Publications signalées
59270Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
HER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyBreast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesMonoclonal and Polyclonal Antibodies Research
Publications récentes
The promyelocytic leukemia PML protein coordinates immune evasion in triple-negative breast cancer via independent and converging mechanisms
Martina Uggé, Cristina Fracassi, Anna Sofia Tascini, Valentina Giansanti et autres
0 citationsCell Death and Differentiation
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer
Justin M. Balko, Luca Licata, Xiao Qian Wang, Matteo Dugo et autres
1 citationnpj Breast Cancer
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study
Laura García‐Estévez, Aditya Bardia, Hope S. Rugo, Lisa A. Carey et autres
5 citationsESMO Open
Analysis of event-free survival (EFS) of stromal tumor infiltrating lymphocytes (sTILs), PD-L1 expression, and their early dynamics in the NeoTRIP trial.
Giampaolo Bianchini, Giulia Viale, Matteo Dugo, Chiun‐Sheng Huang et autres
0 citationsJournal of Clinical Oncology
72P Predictive value of spatially-derived archetypes and tertiary lymphoid structure signature in the NeoTRIP trial
Matteo Dugo, David Venet, Chiun‐Sheng Huang, Xiaoyang Wang et autres
0 citationsESMO Open
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Maurizio Callari, Matteo Dugo, Marco Barreca, Balázs Győrffy et autres
6 citationsNature Communications
Supplementary Data S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Matteo Dugo, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo et autres
0 citations
Supplementary Figure S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Matteo Dugo, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo et autres
0 citations
Supplementary Figure S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Matteo Dugo, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo et autres
0 citations
Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Matteo Dugo, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo et autres
0 citations
Supplementary Figure S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Matteo Dugo, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.